CARLSBAD, Calif.--(BUSINESS WIRE)--Two Contract Research Organizations (CROs) with leading expertise in molecular testing have decided to utilize the new Oncomine Cancer Research panel, which runs on Life Technologies Ion Torrent sequencing instruments, for clinical trial analyses and design.
This comprehensive multi-biomarker assay allows concurrent analyses of DNA and RNA in one workflow, allowing researchers to simultaneously detect all four classes of tumor-driving alterations: single nucleotide variants, copy number variants, tumor suppressors and gene fusions. As CROs and their pharma partners validate their use of this new tool, the potential exists for patients to be more effectively enrolled into clinical trials and study designs made easier.
Help employers find you! Check out all the jobs and post your resume.